(Q36801464)

16 August 2017

1 reference

title

Psychiatric safety of ketamine in psychopharmacology research (English)

1 reference

16 August 2017

Hyun-Sang Cho

3

0 references

author name string

Edward B Perry

1

1 reference

16 August 2017

Joyce A Cramer

2

1 reference

16 August 2017

Ismene L Petrakis

4

1 reference

16 August 2017

Laurence P Karper

5

1 reference

16 August 2017

Angelina Genovese

6

1 reference

16 August 2017

Elizabeth O'Donnell

7

1 reference

16 August 2017

John H Krystal

8

1 reference

16 August 2017

D Cyril D'Souza

9

1 reference

16 August 2017

Yale Ketamine Study Group

10

1 reference

16 August 2017

publication date

16 February 2007

1 reference

16 August 2017

number of pages

8

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

16 August 2017

volume

192

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

253-260

1 reference

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0706-2

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0706-2

Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0706-2

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0706-2

The schizophrenia ketamine challenge study debate.

21 January 2018

1 reference

12 December 2020

Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study

1 reference

12 December 2020

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

12 December 2020

Selective cognitive impairments associated with NMDA receptor blockade in humans

1 reference

12 December 2020

Patterns of use and harms associated with non-medical ketamine use.

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

1 reference

12 December 2020

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

12 December 2020

Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

The NMDA antagonist model for schizophrenia: promise and pitfalls.

1 reference

12 December 2020

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

1 reference

12 December 2020

Computerized evaluation of psychic effects of ketamine.

1 reference

12 December 2020

Ketamine: an update on the first twenty-five years of clinical experience

1 reference

12 December 2020

Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia

1 reference

12 December 2020

Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study

1 reference

12 December 2020

Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions

1 reference

12 December 2020

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans

1 reference

12 December 2020

Antidepressant effects of ketamine in depressed patients

1 reference

12 December 2020

Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers

1 reference

12 December 2020

Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism

1 reference

12 December 2020

An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine?

1 reference

12 December 2020

Effects of ketamine in normal and schizophrenic volunteers

1 reference

12 December 2020

Reliabilities and intercorrelations of eight measures of proneness to psychosis

1 reference

12 December 2020

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

12 December 2020

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

12 December 2020

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

1 reference

12 December 2020

Comparison of ketamine and thiopental in healthy volunteers: effects on mental status, mood, and personality

1 reference

12 December 2020

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

1 reference

12 December 2020

Long-term outcome of patients who receive ketamine during research

1 reference

12 December 2020

Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine

1 reference

12 December 2020

NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy

1 reference

12 December 2020

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

12 December 2020

10.1007/S00213-007-0706-2

Identifiers

DOI

1 reference

16 August 2017

1 reference